To validate the role of TREK‐1 in the pathogenesis of depression in vivo, neuron‐specific AAV with a synapsin‐1 (SYN) promoter shRNA was employed to inhibit TREK‐1 expression in neurons by microinjection into the bilateral hippocampus (Figure 1C,D, Figure S2, and Table S1). This evidence concerns the gene KCNK2 and depressive symptom measurement.